Form 4: DexCom Director Sells Shares via Pre-Arranged Plan
Insider Transaction Report (Form 4)
DexCom Director Richard Alexander Collins sold 3,948 shares of common stock for $55.17 per share, executed under a Rule 10b5-1 plan.
Summary
- Richard Alexander Collins, a Director at DexCom Inc. (DXCM), reported the sale of 3,948 shares of common stock.
- The transaction occurred on November 10, 2025, at a price of $55.17 per share.
- The sale was executed by the Richard A. Collins Revocable Trust, pursuant to a Rule 10b5-1 plan adopted on August 7, 2025, designed for the orderly disposition of shares.
- Following this transaction, Mr. Collins beneficially owns 37,994 shares indirectly through the Trust and 5,074 unvested restricted stock units (RSUs) directly.
- The unvested RSUs were granted on May 8, 2025, and are scheduled to vest on the earlier of the one-year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While a director selling shares can sometimes be perceived negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns, suggesting a planned financial action rather than a reaction to new company-specific information.
Positives
- The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating a non-discretionary transaction and potentially reducing concerns about insider trading based on material non-public information.
Negatives
- A director's sale of shares reduces their direct ownership stake in the company.
Future Outlook
The filing does not contain specific forward-looking statements or guidance beyond the vesting schedule for restricted stock units.
Management Comments
- The sale was made pursuant to a 10b5-1 Plan adopted by the Richard A. Collins Revocable Trust, allowing for the orderly disposition of shares owned by the Trust.
Industry Context
This insider transaction is a routine disclosure and does not inherently reflect broader industry trends or competitive positioning. It is specific to the individual director's financial planning.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Administrative Delegation | Richard Collins granted a Power of Attorney to Jereme Sylvain, Christophe Cantenot, and Stephanie Fong to handle SEC filings, including Forms 3, 4, 5, 13D, 13G, and 144, and manage EDGAR account administration. | 05/15/2025 | This is a standard administrative measure to facilitate timely and accurate SEC filings for the reporting person, ensuring compliance with regulatory requirements. |
Related Party Transactions
- The sale of shares was conducted by the Richard A. Collins Revocable Trust, of which the reporting person is a trustee, making it a related party transaction.
Stakeholder Impact
- Shareholders: The sale by a director, even if pre-planned, slightly reduces insider ownership, which some investors might monitor as a signal of management's confidence.
- Employees: No direct impact on employees is indicated by this filing.
- Customers: No direct impact on customers is indicated by this filing.
- Suppliers: No direct impact on suppliers is indicated by this filing.
- Creditors: No direct impact on creditors is indicated by this filing.
Next Steps
- The remaining 5,074 unvested restricted stock units held by Richard Alexander Collins are expected to vest on the earlier of May 8, 2026, or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.
Key Dates
| Date | Description |
|---|---|
| 05/08/2025 | Grant date for 5,074 unvested restricted stock units to Richard Alexander Collins. |
| 05/15/2025 | Execution date of the Power of Attorney by Richard Collins. |
| 08/07/2025 | Adoption date of the 10b5-1 Plan by the Richard A. Collins Revocable Trust. |
| 11/10/2025 | Transaction date for the sale of 3,948 shares of common stock by the Richard A. Collins Revocable Trust. |
| 2026 | Approximate year of DexCom, Inc.'s Annual Meeting of Stockholders, which is a potential vesting date for unvested restricted stock units. |
Keywords
DexCom, DXCM, Insider Trading, Form 4, Director Sale, 10b5-1 Plan, Common Stock, Restricted Stock Units, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.